Antithymocyte globulin for graft-versus-host disease prophylaxis: mistakenly maligned

"Antithymocyte globulin for graft-versus-host disease prophylaxis: mistakenly maligned." Leukemia & Lymphoma, 56(4), pp. 841–842

Notes

Two prospective randomized studies presented at the 2014 ASH meetings provide further evidence of the utility of ATG:

The Canadian Bone Marrow Transplant group showed that the addition of thymoglobulin reduced the need for prolonged immunosuppression after unrelated donor transplant without increase in relapse or nonrelapse mortality.(Walker et al, abstract 38).

A European multicenter study showed that the addition of ATG-Fresenius after HLA-identical sibling transplant prevented limited and extensive chronic GVHD without increases in relapse or infections (Bonifazi et al, abstract 37).

Potential conflict of interest

Disclosure forms provided by the authors are available with the full text of this article at www.informahealthcare.com/lal.